Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
Date:8/9/2012

SAN FRANCISCO, Aug. 9, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2012.

Cash, cash equivalents, and investments at June 30, 2012 were $477.1 million as compared to $498.8 million at March 31, 2012.
This cash balance does not include the proceeds from the $125.0 million issuance of Senior Secured Notes that closed on July 11, 2012.

"I continue to be extremely pleased with Nektar's performance," said Howard W. Robin, President and Chief Executive Officer of Nektar. "The Phase 3 program for naloxegol is on track and AstraZeneca and Nektar plan to announce high-level results from the pivotal efficacy studies in the fourth quarter of 2012. NKTR-181 received Fast-Track designation from the FDA reflecting the important medical need addressed by this new opioid molecule. In July, we further strengthened our financial position with the $125 million private placement of Senior Secured Notes with no equity dilution to our shareholders."

Revenue for the second quarter of 2012 was $23.7 million, an increase as compared to $17.3 million in the second quarter of 2011. Year-to-date revenue for 2012 was $41.6 million, an increase as compared to $28.6 million for the first half of 2011.  The increases in 2012 compared to 2011 are due to a combination of increased product sales, royalties, and other collaboration revenues.  

Total operating costs and expenses in the second quarter of 2012 were $50.7 million as compared to $51.6 million in the second quarter of 2011.
Total operating costs and expenses for the first half of 2012 were $106.6 million as compared to $96.8 million in the first half of 2011.  Total operating expenses in the first half of 2012 increased as a result of higher cost of goods related to increased product sales as well as increase
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
8. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... -- Hospira, Inc. (NYSE: HSP ), ... spoke about the importance of extrapolation in bringing biosimilars ... annual European Biosimilars Group conference in London ... publication of a pivotal white paper titled, "Why ... biosimilars." Speaking at the EGA conference, ...
(Date:4/23/2015)... , April 24, 2015  AbbVie (NYSE: ABBV ... Administration (FDA) has accepted its New Drug Application (NDA) ... two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), ... of adults with chronic genotype 4 (GT4) hepatitis C ... first all-oral, interferon-free therapy being evaluated by the FDA ...
(Date:4/23/2015)... 23, 2015 Once again, BeaconMedaes is meeting ... to patient safety. BeaconMedaes, priority is to ... disease. The next generation Zone Valve Box ... are now mounted in the assembly, allowing for ease ... ceiling tiles potentially releasing dust spores and other bacteria ...
Breaking Medicine Technology:Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2
(Date:4/27/2015)... April 27, 2015 The ... 2015” provides comparative analysis on the therapeutic ... strengthens R&D pipelines by identifying new targets ... products. Complete report on H1 2015 pipeline ... data tables and 14 figures, spread across ...
(Date:4/27/2015)... The Radiology Business Management Association ... applied business information and intelligence, is proud to announce ... newsletter for its more than 2,000 members. , “RBMA ... news sources in that it is exclusively devoted to ... radiology. The newsletter is produced in cooperation with Thorn ...
(Date:4/27/2015)... Final Cut Pro X users ... from Pixel Film Studios. A telestrator is a device that ... moving or still video image. Telestrators are often used in ... or incoming weather patterns. , After users are done drawing,users ... frame slider to control the speed of the animation. This ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 PREVENT Life ... expanding its Texas operations with the addition of an ... life safety services to a growing customer base, Curtis ... as a new Senior Account Manager. Curtis has been ... support existing customers throughout the Houston area and beyond. ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Launched ... Amazon engineer, ZendyBeauty offered consumers a way to ... at affordable prices. Using a patent-pending Pick Your ... standard procedures like Botox®, laser hair removal and ... their staff had gaps in their schedules. This ...
Breaking Medicine News(10 mins):Health News:Essential Thrombocythemia Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Essential Thrombocythemia Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Essential Thrombocythemia Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:Radiology Business Management Association Launches Weekly Legislative and Policy Newsletter 2Health News:Pixel Film Studios releases ProTelestrator for Final Cut Pro X. 2Health News:PREVENT Life Safety Services Welcomes Curtis Rice as a New Senior Account Manager in Houston, TX 2Health News:ZendyBeauty Is Pleased to Announce the Expansion and Rebranding of the Company as ZendyHealth.com 2
... obesity is widely viewed as contributing to type 2 ... Hospital Boston report that two proteins activated by inflammation ... and that boosting the activity of these proteins ... mice. The research, led by Umut Ozcan, ...
... have developed a formula to predict which heart transplant patients ... their surgeries, information that could help medical teams figure out ... organs. "Donor hearts are a limited resource," says John ... Hopkins University School of Medicine and the senior author of ...
... and his group at the McCormick School of Engineering ... previously ignored mechanism in modeling how humans travel. ... professor of engineering sciences and applied mathematics, hopes to ... of disease and the spread of human-mediated bioinvasions. ...
... (Sept. 2, 2011) -- Medical students who practiced on ... scored significantly higher on their final examinations than did ... an obstetric clerkship. Results of the University of ... 2011 issue of the high-impact journal Obstetrics & ...
... Sept. 2 (HealthDay News) -- Joining a gym is the first ... better shape. But for many, joining is also the last step ... Courthouse Athletic Club in Salem, Ore. Some come once or ... said. Others don,t show up at all. "There,s an idea ...
... HealthDay Reporter , THURSDAY, Sept. 1 (HealthDay News) -- ... health problem at some point in their life, a new ... them. Mental health issues run the gamut from depression ... suffering presently do not get help, experts say. ...
Cached Medicine News:Health News:New tactic for controlling blood sugar in diabetes contradicts current view of the disease 2Health News:Researchers develop new way to predict heart transplant survival 2Health News:Researchers investigate new mechanism for predicting how diseases spread 2Health News:Simulation training in obstetric clerkship improves medical students' examination scores 2Health News:Simulation training in obstetric clerkship improves medical students' examination scores 3Health News:To Get Up and Get Moving, Joining a Gym Might Help 2Health News:Half of Americans Will Suffer From Mental Health Woes, CDC Says 2Health News:Half of Americans Will Suffer From Mental Health Woes, CDC Says 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: